Please note some content on this site is no longer supported on Internet Explorer 8, we recommend you upgrade your browser
Most recently with Roche 2007-2010, Mikael held global clinical responsibility for the HER family of compounds including Herceptin, Pertuzumab and Tarceva, and acted as a Cluster Head for the HER2 Franchise. Prior to Roche, Mikael was Vice President, Oncology MDC, Europe, at GlaxoSmithKline and worked across several key clinical development roles at AstraZeneca.
Chief Scientific Adviser.
Co-founder and inventor of Targovax peptide cancer immunotherapy technology.
Professor emeritus in immunology (The Norwegian Radium Hospital).
More than 40 years of research experience within the field of immunotherapy of cancer. Internationally recognized opinion leader. Author and co-author of many scientific articles and co-inventor of several patents.
Chief Physician of the Clinic for Oncology and Hematology at the Nordwest Krankenhaus in Frankfurt, Elke is also the Director of the Clinical Trial Center at her hospital and a distinguished cancer immunotherapy opinion leader in Europe.
Investor Email Alerts